Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity ( (CELC) ) has issued an update.
On February 11, 2026, Celcuity’s board expanded from seven to eight members and appointed pharmaceutical industry veteran Charles (Chip) R. Romp as an independent director for a term running through the 2026 annual meeting. He will receive standard non-employee director compensation, including a prorated restricted stock grant that vests by April 30, 2026, and currently has not been assigned to any board committees.
Announced publicly on February 12, 2026, Romp’s appointment adds deep oncology commercialization expertise as Celcuity advances gedatolisib toward potential regulatory milestones and prepares for possible market launch. His background leading major oncology franchises at Seagen, Genentech, and now Secura Bio strengthens the company’s commercial readiness and could help shape strategy around building an oncology franchise centered on gedatolisib.
The most recent analyst rating on (CELC) stock is a Hold with a $118.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, accelerating losses/cash burn, and higher leverage). This is partially offset by constructive technical strength and a positive earnings-call outlook driven by strong clinical data, NDA progress, and stated funding runway; valuation remains difficult given negative earnings and no dividend.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
Celcuity Inc., headquartered in Minneapolis, is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead candidate, gedatolisib, is a pan-PI3K and mTORC1/2 inhibitor being evaluated in several Phase 3 and Phase 1/2 trials for HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.
Average Trading Volume: 862,108
Technical Sentiment Signal: Buy
Current Market Cap: $4.82B
See more insights into CELC stock on TipRanks’ Stock Analysis page.